Topical pexiganan cream 0.8% — Competitive Intelligence Brief

Topical pexiganan cream 0.8% (Topical pexiganan cream 0.8%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial peptide. Area: Infectious Disease / Dermatology.

phase 3 Antimicrobial peptide Bacterial cell membrane Infectious Disease / Dermatology Small molecule

Target snapshot

Topical pexiganan cream 0.8% (Topical pexiganan cream 0.8%) — Dipexium Pharmaceuticals, Inc.. Pexiganan is an antimicrobial peptide that disrupts bacterial cell membranes, killing a broad spectrum of bacteria including antibiotic-resistant strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topical pexiganan cream 0.8% TARGET	Topical pexiganan cream 0.8%	Dipexium Pharmaceuticals, Inc.	phase 3	Antimicrobial peptide	Bacterial cell membrane
Silvadene	Silver Sulfadiazine	Pfizer	marketed	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
CHG antiseptic body cleanser	CHG antiseptic body cleanser	Baycrest	marketed	Antimicrobial antiseptic	Bacterial cell membrane
Neutrogena Rapid Clear®	Neutrogena Rapid Clear®	GlaxoSmithKline	marketed	Topical antimicrobial/keratolytic agent	Cutibacterium acnes (bacterial cell membranes and proteins)
Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Derm Research, PLLC	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Clindamycin and BPO 5% gel	Clindamycin and BPO 5% gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)
adapalene/benzoyl peroxide	adapalene/benzoyl peroxide	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial peptide class)

1. Abeona Therapeutics, Inc · 1 drug in this class
2. Dipexium Pharmaceuticals, Inc. · 1 drug in this class
3. Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 drug in this class
4. Maruho Co., Ltd. · 1 drug in this class
5. Tufts Medical Center · 1 drug in this class